about
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective.Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutationNephrotoxicity of recent anti-cancer agents.Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.Safety profile of new anticancer drugs.Sorafenib for the treatment of renal cancer.Complications of oncologic therapy in the abdomen and pelvis: a review.Molecular targets on the horizon for kidney and urothelial cancer.Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.Nephrotoxicity of anticancer treatment.Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib.Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors.The Inverse Association between the Baseline Renal Function and Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Molecular-Targeted Agents.Neither creatinine nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents.Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents.
P2860
Q30382892-FAC7FB46-E5BB-4C02-A4FA-30FE21587093Q30405427-9B7B2D69-B819-4280-B902-2F00625E4024Q33955857-49A87BE9-0F09-4209-BBFE-1F16AF93D4EEQ35310741-D362A08D-7082-4321-B212-56AA53F86B6FQ37598818-54BBE4F4-8820-46E1-AA10-05775E95EDCFQ37696502-FE80EF72-71C3-4B12-9778-59372091A811Q37977494-8BD2CA81-69EA-4811-BCE8-837BC88A2D39Q38014349-4CBA5AAE-F226-47D8-93E9-70BC6B4AE7E8Q38132039-E6F28D57-476F-4754-BF4D-49129043C08BQ38225636-730D6443-228A-4F71-A311-D384D8363FA1Q39198933-47EDD27F-41B5-42AE-A66D-073A252F5598Q41496075-1698E1FB-6A2F-4685-BE06-229F1894972EQ42061300-90698A0C-C4B8-471B-9F16-629CBEED2BC1Q42371674-841F585F-2218-4E0A-AA77-65D64C3968B7Q46250094-33CDC9DD-B278-472B-912D-7E6849C0B51CQ47144097-3BE709E6-11F1-4D9B-9D04-CC46CCEF6C41Q49097109-DD3C6693-B0C0-4351-B89F-EA9692F75305Q52906446-E2B06DE5-9CA7-49C2-9520-0B248EC14CF9
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal toxicity of targeted therapies.
@en
Renal toxicity of targeted therapies.
@nl
type
label
Renal toxicity of targeted therapies.
@en
Renal toxicity of targeted therapies.
@nl
prefLabel
Renal toxicity of targeted therapies.
@en
Renal toxicity of targeted therapies.
@nl
P1433
P1476
Renal toxicity of targeted therapies.
@en
P2093
Bertrand Billemont
Ronan J Kelly
P2860
P2888
P304
P356
10.1007/S11523-009-0109-X
P50
P577
2009-04-01T00:00:00Z